gefapixant
Jump to navigation
Jump to search
Indications
* FDA rejects approval, benefit not clinically meaningful
Dosage
- 45 mg PO BID Adverese effects:
- taste disturbance
Mechanism of action
Clinical trials
- in phase 3 trial
More general terms
References
- ↑ Boyles S Gefapixant Reduces Chronic Cough in Phase III Trials - But taste distortion was frequent AE at active dosage. MedPage Today September 9, 2020 https://www.medpagetoday.com/meetingcoverage/ers/88515
- ↑ Short E Drug Candidate for Chronic Cough Rejected by FDA Panel. Gefapixant's benefit not clinically meaningful enough, panelists say MedPage Today November 17, 2023 https://www.medpagetoday.com/pulmonology/generalpulmonary/107440